Related Experiment Videos
Waldenström macroglobulinemia terminating in acute leukemia: a report of three cases
Abstract:
Acute leukemia was observed to develop in three patients with Waldenstöm macroglobulinemia. Each patient had been treated with cytotoxic drug therapy. Pancytopenia preceded the onset of the terminal leukemia in two of the three cases. The acute leukemias were all of acute myelogenous type. All of the patients died soon after the development of the terminal leukemia. A number of recent reports have documented acute terminal leukemia in patients with macroglobulinemias and multiple myeloma, as well as other malignant and nonmalignant diseases. The role of the cytotoxic drugs, especially chlorambucil, cyclophosphamide, and melphalan, in leukemogenesis has been raised by these recent reports.
Insights
Cytotoxic drug therapy may increase the risk of acute myeloid leukemia in patients with Waldenström macroglobulinemia. This aggressive leukemia often proved fatal shortly after diagnosis.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Waldenström macroglobulinemia is a rare lymphoproliferative disorder.
- Cytotoxic drugs are commonly used in treating lymphoproliferative disorders.
Observation:
- Three patients with Waldenström macroglobulinemia developed acute leukemia after cytotoxic drug treatment.
- Pancytopenia was observed prior to leukemia onset in two patients.
- The leukemias were acute myelogenous type.
Findings:
- Cytotoxic agents, including chlorambucil, cyclophosphamide, and melphalan, are implicated in leukemogenesis.
- Acute terminal leukemia has been reported in patients with macroglobulinemias and multiple myeloma.
Implications:
- Further research is needed to understand the leukemogenic potential of cytotoxic drugs in hematologic malignancies.
- This highlights the importance of monitoring patients undergoing cytotoxic therapy for potential secondary malignancies.